

55. Mango R, Clementi F, Borgiani P, Forleo GB, Federici M, Contino G, et al. Association of single nucleotide polymorphisms in the oxidized LDL receptor 1 (OLR1) gene in patients with acute myocardial infarction. *J Med Genet* 2003; **40**: 933–936.
56. Chen Q, Reis SE, Kammerer C, Craig WY, LaPierre SE, Zimmer EL, et al. Genetic variation in lectin-like oxidized low-density lipoprotein receptor 1 (LOX1) gene and the risk of coronary artery disease. *Circulation* 2003; **107**: 3146–3151.
57. Mango R, Biocca S, del Vecchio F, Clementi F, Sangiuolo F, Amati F, et al. In vivo and in vitro studies support that a new splicing isoform of OLR1 gene is protective against acute myocardial infarction. *Circ Res* 2005; **97**: 152–158.
58. Tatsuguchi M, Furutani M, Hinagata J, Tanaka T, Furutani Y, Imamura S, et al. Oxidized LDL receptor gene (OLR1) is associated with the risk of myocardial infarction. *Biochem Biophys Res Commun* 2003 **28**: 247–250.
59. Knowles J, Assimes T, Boerwinkle E, Fortmann S, Go A, Grove M, et al. Failure to replicate an association of SNPs in the oxidized LDL receptor gene (OLR1) with CAD. *BMC Med Genet* 2008; **9**: 23.
60. Biocca S, Falconi M, Filesi I, Baldini F, Vecchione L, Mango R, et al. Functional analysis and molecular dynamics simulation of LOX-1 K167N polymorphism reveal alteration of receptor activity. *PLoS One* 2009; **4**: e4648.
61. Murase T, Kume N, Kataoka H, Minami M, Sawamura T, Masaki T, et al. Identification of soluble forms of lectin-like oxidized LDL receptor-1. *Arterioscler Thromb Vasc Biol* 2000; **20**: 715–720.
62. Mitsuoka H, Kume N, Hayashida K, Inui-Hayashiada A, Aramaki Y, Toyohara M, et al. Interleukin 18 stimulates release of soluble lectin-like oxidized LDL receptor-1 (sLOX-1). *Atherosclerosis* 2009; **202**: 176–182.
63. Hayashida K, Kume N, Murase T, Minami M, Nakagawa D, Inada T, et al. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: A novel marker for early diagnosis. *Circulation* 2005; **112**: 812–818.
64. Kakutani M, Ueda M, Naruko T, Masaki T, Sawamura T. Accumulation of LOX-1 ligand in plasma and atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits: Identification by a novel enzyme immunoassay. *Biochem Biophys Res Commun* 2001; **282**: 180–185.
65. Sato Y, Nishimichi N, Nakano A, Takikawa K, Inoue N, Matsuda H, et al. Determination of LOX-1-ligand activity in mouse plasma with a chicken monoclonal antibody for ApoB. *Atherosclerosis* 2008; **200**: 303–309.
66. Oka K, Yasuhara M, Suzumura K, Tanaka K, Sawamura T. Antioxidants suppress plasma levels of lectinlike oxidized low-density lipoprotein receptor-ligands and reduce atherosclerosis in watanabe heritable hyperlipidemic rabbits. *J Cardiovasc Pharmacol* 2006; **48**: 177–183.
67. Holvoet P, Lee DH, Steffes M, Gross M, Jacobs DR Jr. Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. *JAMA* 2008; **299**: 2287–2293.
68. Holvoet P, Collen D, Van de Werf F. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. *JAMA* 1999; **281**: 1718–1721.
69. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. *N Engl J Med* 2005; **353**: 46–57.
70. Ishino S, Mukai T, Kuge Y, Kume N, Ogawa M, Takai N, et al. Targeting of lectinlike oxidized low-density lipoprotein receptor 1 (LOX-1) with <sup>99m</sup>Tc-labeled anti-LOX-1 antibody: Potential agent for imaging of vulnerable plaque. *J Nucl Med* 2008; **49**: 1677–1685.

# Role of LOX-1 in Monocyte Adhesion-Triggered Redox, Akt/eNOS and Ca<sup>2+</sup> Signaling Pathways in Endothelial Cells

NOBUO SAKAMOTO,<sup>1</sup> TOSHIYUKI ISHIBASHI,<sup>1\*</sup> KOICHI SUGIMOTO,<sup>1</sup> TATSUYA SAWAMURA,<sup>2</sup> TAKAYUKI SAKAMOTO,<sup>1</sup> NOBUTAKA INOUE,<sup>2</sup> SHU-ICHI SAITOH,<sup>1</sup> MASASHI KAMIOKA,<sup>1</sup> HIRONORI UEKITA,<sup>1</sup> HIROSHI OHKAWARA,<sup>1</sup> KOJI SUZUKI,<sup>3</sup> TAMIO TERAMOTO,<sup>4</sup> YUKIO MARUYAMA,<sup>1,5</sup> AND YASUCHIKA TAKEISHI<sup>1</sup>

<sup>1</sup>First Department of Internal Medicine, Fukushima Medical University, Fukushima, Japan

<sup>2</sup>Department of Vascular Physiology, National Cardiovascular Center Research Institute, Suita, Japan

<sup>3</sup>Department of Molecular Pathobiology, Mie University Graduate School of Medicine, Tsu, Japan

<sup>4</sup>Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan

<sup>5</sup>Hoshi General Hospital, Koriyama, Japan

This study was conducted to examine the role of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in monocyte adhesion-induced redox-sensitive, Akt/eNOS and Ca<sup>2+</sup> signaling pathways in endothelial cells (ECs). LOX-1 was blocked by an antibody-neutralizing LOX-1 TS92 or small interfering RNA. In cultured human aortic ECs, monocyte adhesion activated Rac1 and p47<sup>phox</sup>, and increased NADPH oxidase activity and reactive oxygen species (ROS) generation within 30 min and NF-κB phosphorylation within 1 h, resulting in redox-sensitive gene expression. Akt and eNOS phosphorylation was induced 15 min after adding monocytes and returned to control level after 30 min, whereas NO production was not altered by monocyte adhesion. Blockade of LOX-1 blunted the monocyte adhesion-triggered redox-sensitive signaling pathway and Akt/eNOS phosphorylation in ECs. Both endothelial intracellular Ca<sup>2+</sup> mobilization and Ca<sup>2+</sup> influx caused by monocyte attachment were markedly attenuated by pretreatment of ECs with TS92. This suggests that LOX-1 is involved in redox-sensitive, Akt/eNOS and Ca<sup>2+</sup> signaling pathways in monocyte adhesion to ECs independent of oxidized low-density lipoprotein (ox-LDL). Furthermore, blockade of Ca<sup>2+</sup> inhibited monocyte adhesion-triggered Rac1 and p47<sup>phox</sup> activation and ROS generation in ECs, whereas Ca<sup>2+</sup> signaling was suppressed by blockade of NADPH oxidase and ROS generation. Finally, TS92 blocked the monocyte adhesion to ECs stimulated with or without tumor necrosis factor-α or ox-LDL. We provide evidence that LOX-1 plays a role in redox-sensitive, Akt/eNOS and Ca<sup>2+</sup> signaling pathways in monocyte adhesion to ECs independent of the ox-LDL-LOX-1 axis.

J. Cell. Physiol. 220: 706–715, 2009. © 2009 Wiley-Liss, Inc.

Monocyte adhesion to endothelial cells (ECs) of the vascular wall is a priming event in the progression of atherosclerosis and the redox-sensitive gene expression in ECs including monocyte chemoattractant protein-1 (MCP-1), intercellular adhesion molecule-1 (ICAM-1), tissue factor (TF), and plasminogen activator inhibitor-1 (PAI-1) (Ross, 1999; Libby, 2002; Ishibashi et al., 2003). We have recently reported the RhoA-mediated NF-κB and Ca<sup>2+</sup>-dependent pathways in monocyte adhesion-induced TF and PAI-1 expression in ECs, as well as the crucial role of RhoA activation in endothelial dysfunction (Yokoyama et al., 2002; Ishibashi et al., 2003; Ohkawara et al., 2005; Sakamoto et al., 2007). However, the detailed mechanism(s) by which monocyte adhesion to ECs induces redox-sensitive gene expression and Ca<sup>2+</sup> signaling is not well understood.

Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) was identified as a major receptor for oxidized low-density lipoprotein (LDL) which is potent for inflammation and reactive oxygen species (ROS) generation, and this receptor is uniquely expressed in the ECs of large arteries (Sawamura et al., 1997). Oxidized LDL-triggered intracellular ROS generation has been shown to be mediated via LOX-1, indicating that LOX-1 activation is responsible for oxidized LDL-induced redox-sensitive gene expression including ICAM-1 and vascular cell adhesion molecule 1 (VCAM-1) which are associated with monocyte adhesion to ECs (Cominacini

et al., 2000; Min et al., 2005). In addition, ROS downregulate endothelium-derived nitric oxide (NO) which regulate vascular homeostasis, and Akt/eNOS pathway is crucial for NO production.

In the present study, we hypothesized that endothelial LOX-1 plays a role in the redox-sensitive, Akt/eNOS and Ca<sup>2+</sup> signaling pathways in monocyte adhesion to ECs independent of the oxidized LDL-LOX-1 axis.

Contract grant sponsor: Japan Society for the Promotion of Science;  
Contract grant numbers: 14370232, 19590804, 1979056.  
Contract grant sponsor: Takeda Science Foundation.  
Contract grant sponsor: The Uehara Memorial Foundation.  
Contract grant sponsor: Fukushima Medical University Research Project.

\*Correspondence to: Toshiyuki Ishibashi, First Department of Internal Medicine, Fukushima Medical University, Fukushima 960-1295, Japan. E-mail: masaishi@fmu.ac.jp

Received 12 March 2009; Accepted 6 April 2009

Published online in Wiley InterScience  
(www.interscience.wiley.com.), 18 May 2009.  
DOI: 10.1002/jcp.21818



## Materials and Methods

### Materials

The sources of most of the conventional reagents for the present study were described previously (Ishibashi et al., 2003; Sakamoto et al., 2005, 2007). TS92, a neutralizing antibody to LOX-1, was used for inhibition of LOX-1 and a neutralizing antibody to human PECAM-1 was purchased from BioLegend (San Diego, CA) (Sawamura et al., 1997). Fluorescent probes, 2',7'-bis-(2-carboxyethyl)-5-(6)-carboxyfluorescein acetoxymethyl ester (BCECF-AM) and fura-2/acetoxymethyl ester were purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan), a ROS-sensitive fluorescent probe 2',7'-dichlorodihydro-fluorescein-diacetate (H<sub>2</sub>DCF-DA) from Molecular Probes (Eugene, OR), and diphenyleneiodonium (DPI), an inhibitor of NADPH oxidase and *N*-acetylcysteine (NAC), an antioxidant, were from Sigma-Aldrich Co. (St. Louis, MO).

### Isolation of human peripheral blood monocytes

Human peripheral blood monocytes were isolated from normal volunteers and the purity of isolated monocytes was greater than 95% as determined by flow cytometry and cytohistochemistry as described previously (Nagata et al., 2001; Ishibashi et al., 2003). Ethical approval was obtained from Fukushima Medical University for the study.

### Cell culture

Human aortic ECs (Clonetics, Inc., Walkersville, MD and Sanko Junyaku Co., Ltd., Tokyo, Japan) were cultured as described previously and used for all experiments after 5–10 passages (Yokoyama et al., 2002; Ohkawara et al., 2005). We added monocytes ( $5 \times 10^5$  or  $1 \times 10^6$  cells) to near-confluent ECs (Cominacini et al., 2000) for the below-described purposes. We recently reported the expression of relatively monocyte-specific antigen CD14 to clarify the potential contamination of ECs with residual monocytes by Western blotting after the cultures were washed extensively to remove the monocytes, indicating the negligible effect of residual monocytes on CD14 expression in ECs (Sakamoto et al., 2005).

### Measurement of intracellular ROS generation

Detection of intracellular ROS generation was performed by a previously established method using H<sub>2</sub>DCF-DA (Cominacini et al., 2000). Monocytes ( $5 \times 10^5$  cells) were added to nearly confluent ECs cultured on 60-mm dishes and incubated at 37°C for 15, 30, and 60 min, respectively. Fluorescence was measured using a confocal microscope (Olympus Co. Ltd., Tokyo, Japan) at excitation and emission wavelength of 475 and 525 nm, respectively. Images were stored in a computer and the intensity of fluorescence was quantitatively analyzed by the NIH Image Program (ImageJ).

### Membrane translocation of Rac1 and p47<sup>phox</sup>

The activities of Rac1 and p47<sup>phox</sup>, components of the NADPH oxidase, were determined by membrane translocation, followed by Western blotting as described previously (Yokoyama et al., 2002; Ishibashi et al., 2003). For immunoblotting, we used a mouse monoclonal antibody to Rac1 (Upstate Biotechnology, Lake Placid, NY) diluted 1:1,000 and a rabbit polyclonal antibody to p47<sup>phox</sup> (Santa Cruz Biotechnology Inc., Santa Cruz, CA) diluted 1:200.

### Determination of NF-κB activation

NF-κB phosphorylation was determined by Western blotting using an anti-phospho-NF-κB p65 antibody (Ser-536, dilution 1:1,000,

Cell Signaling Technology, Inc., Beverly, MA) as described previously (Ishibashi et al., 2003; Sakamoto et al., 2005).

### Measurement of NADPH oxidase activity

The enzymatic activities of NADPH oxidase of homogenates of the ECs were assessed by lucigenin-enhanced chemiluminescence (L-CL) as previously described (Ejiri et al., 2005). The assay solution contained 50 mmol/L HEPES (pH 7.4), 1.0 mmol/L EDTA, 6.5 mmol/L MgCl<sub>2</sub>, 5.0 μmol/L lucigenin as an electron acceptor, and 1 mmol/L NADPH as a substrate. After preincubation at 37°C for 10 min, the reaction was started by adding 50 μg of homogenate. Final volume of the reaction solution was 1.0 ml. Photon emission was continuously recorded for 15 min with a CL reader (ALOKA, BLR-201). The chemiluminescent signals observed in the absence of homogenates were subtracted from the chemiluminescence signals of the samples. The chemiluminescence signal was corrected for the protein concentration of each cell homogenate and expressed as counts per minute (cpm) per milligram protein for a 15-min period. In some experiments, the homogenates were preincubated with 10 μmol/L DPI, a selective NADPH oxidase inhibitor, for 20 min before L-CL measurement.

### Small interfering RNA (siRNA)

LOX-1 expression was inhibited by siRNA 5'-GAGGCCAUUCCGAAUCAAGA-3' (sense strand) (RNAi Co., Ltd., Tokyo, Japan) (Naito et al., 2004). ECs were transfected with double-stranded siRNA in serum-free medium mixed with oligofectamine (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. Four hours after transfection, ECs were incubated in a medium containing 2% fetal bovine serum (FBS) for 48 h. Alternatively, ECs were treated with an irrelevant siRNA 5'-GUACCGCACGUCAUUCGCAUC-3' (sense strand) as a negative control. LOX-1 protein suppression by siRNA was evaluated by fluorescent immunohistochemical staining using a primary antibody against LOX-1 (termed TS20) and anti-mouse Alexa 488 (Molecular Probes) as a secondary antibody. The fluorescent intensity of LOX-1 expression was quantitatively analyzed by the ImageJ.

### Western blotting

ECs were pretreated with 10 μmol/L DPI and 10 mmol/L NAC for 30 min, and 5 μg/ml TS92 for 1 h. ECs treated with TS92 were washed three times before adding monocytes. Monocytes were then added to ECs and the cells were cultured for 18 h, followed by Western blotting after washing out monocytes. After scanning immunoblots onto a computer (EPSON GT5500ART, Suwa, Japan), individual bands were analyzed for optical density using NIH image as described previously (Ohkawara et al., 2005; Sakamoto et al., 2005, 2007).

### Determination of EC surface TF activity

TF activity was determined as factor X activation by factor VIIa/TF complex on ECs as described previously (Ishibashi et al., 2003).

### Determination of Akt and eNOS phosphorylation

Akt and eNOS phosphorylation in response to monocyte adhesion in ECs was determined by Western blotting at various time intervals after adding monocytes. Anti-phospho-Akt (Ser-473, dilution 1:1,000, Cell Signaling Technology, Inc.) and anti-phospho-eNOS (Ser-1177; dilution 1:1,000, Cell Signaling Technology, Inc.) antibodies were used as a primary antibody.

### NO detection

Measurement of NO in cell culture medium was electrochemically performed using NO-sensitive electrodes (ISO-NOPF, 100)



manufactured by WPI (Sarasota, FL) as described previously (Shibuki and Okada, 1991; Tsukahara et al., 1993). Briefly, the NO probe consists of a working argon anode and a reference/counter electrode. A gas-permeable membrane covers the tip of the electrode. NO diffusing across the electron membrane is oxidized on the surface of prepolarized working electrode, resulting in electrical current. The magnitude of the current, being proportional to the activity of NO in a sample, was detected by an amplifier and registered on a chart recorder.

#### Measurement of intracellular $\text{Ca}^{2+}$ concentrations ( $[\text{Ca}^{2+}]_i$ )

ECs were cultured in 35-mm glass bottom dishes (MatTek Co., Ashland, MA), and intracellular  $\text{Ca}^{2+}$  concentrations ( $[\text{Ca}^{2+}]_i$ ) were measured in response to monocyte attachment in the absence or presence of external  $\text{Ca}^{2+}$  as described previously (Yokoyama et al., 2002; Sakamoto et al., 2005). Intracellular  $\text{Ca}^{2+}$  mobilization was the value in the absence of external  $\text{Ca}^{2+}$ , whereas the  $\text{Ca}^{2+}$  influx was defined as the value when the  $\text{Ca}^{2+}$  value in the absence of external  $\text{Ca}^{2+}$  was subtracted from the value in the presence of external  $\text{Ca}^{2+}$ .

#### Monocyte adhesion assay

Monocyte adhesion to ECs was determined by a previously established method (Fischer et al., 2005). ECs cultured on 12-well plates were pretreated with or without 10 ng/ml TNF- $\alpha$  or 100  $\mu\text{g}/\text{ml}$  oxidized LDL overnight and then treated with 5  $\mu\text{g}/\text{ml}$  TS92 for inhibition of LOX-1 for 1 h. In parallel, monocytes were labeled with 3  $\mu\text{g}/\text{ml}$  BCECF-AM at 37°C for 30 min. Labeled monocytes ( $2.5 \times 10^5$  cells) were added to ECs after washing out the antibodies and incubated at 37°C for 30 min. After aspiration of the medium, nonadherent monocytes were removed by three washing steps. Adherent monocytes were lysed in 0.1 mol/L Tris/0.1% (w/v) Triton X-100, and fluorescence was measured by a SPECTRA microplate reader (Molecular Devices Co., Sunnyvale, CA) at an excitation of 492 nm and emission of 535 nm.

#### Preparation of oxidized LDL

Oxidized LDL was prepared as described previously (Yokoyama et al., 1998). Human native LDL (density 1.019–1.063 g/ml) was isolated from serum of fasting normolipidemic volunteers by sequential ultracentrifugation and was stored at 4°C in 0.3 mmol/L EDTA. Oxidized LDL was prepared by incubating native LDL for 24 h at 4°C in phosphate-buffered saline (PBS) containing 5  $\mu\text{mol}/\text{L}$   $\text{CuSO}_4$ , and then extensively dialyzed against PBS and sterilized by filtration.

#### Statistical analysis

Statistical analyses were performed using ANOVA with Scheffé's post hoc test if appropriate. Data are expressed as means  $\pm$  SD. A value of  $P < 0.05$  was considered significant.

## Results

### Redox-sensitive signaling pathway in ECs by monocyte adhesion

Monocyte adhesion generated intracellular ROS in ECs in a time-dependent manner. Figure 1A shows the time course of the levels of intracellular ROS generation in ECs in response to monocyte adhesion from 15 to 60 min after adding monocytes. To determine the source of ROS generation induced in ECs by monocyte adhesion, we treated the ECs with 10  $\mu\text{mol}/\text{L}$  DPI and 10 mmol/L NAC for 30 min before adding monocytes. DPI, as well as NAC, prevented the ROS generation caused by monocyte adhesion in ECs 60 min after adding monocytes (Fig. 1B).

We next determined whether Rac1 and p47<sup>phox</sup> are activated by monocyte adhesion in ECs. Membrane translocation assays showed that the levels of Rac1 and p47<sup>phox</sup> in membrane fractions of ECs were increased 30 min after adding monocytes and that monocyte adhesion decreased the levels of Rac1 and p47<sup>phox</sup> in cytosol fractions (Fig. 1C). NADPH oxidase activity in ECs was enhanced by monocyte adhesion 15 min after adding monocytes as described later in Figure 2C.

Monocyte adhesion increased the levels of NF- $\kappa$ B phosphorylation in ECs 1 h after adding monocytes, which was prevented by the pretreatment with 10  $\mu\text{mol}/\text{L}$  DPI and 10 mmol/L NAC for 30 min before adding monocytes (Fig. 1D).

We then examined the effect of monocyte adhesion on redox-sensitive gene expression in ECs. Western blotting revealed that monocyte adhesion to ECs induced an increase in the expression of MCP-1, ICAM-1, TF, and PAI-1 in ECs after 18 h of coculture as described later in Figure 3A, which was prevented by pretreatment of ECs with DPI and NAC (data not shown). DPI and NAC also suppressed the increased EC surface TF activity caused by monocyte adhesion (data not shown). These results suggest the redox-sensitive signaling pathway of NADPH oxidase/ROS/NF- $\kappa$ B in monocyte adhesion-triggered gene expression in ECs.

### Role of LOX-1 in monocyte adhesion-triggered redox signaling pathway and gene expression

Next, we analyzed the effect of inhibition of LOX-1 on the redox-sensitive signaling pathway and gene expression induced in ECs by monocyte adhesion. The increased ROS generation in ECs induced by monocyte adhesion was prevented by pretreatment of ECs with antibodies to LOX-1, ICAM-1, and VCAM-1 for 1 h before adding monocytes to ECs, whereas pretreatment with an antibody against PECAM-1, which was not involved in monocyte adhesion, did not affect monocyte adhesion-triggered endothelial ROS generation (Fig. 2A). We then determined the effect of inhibition of LOX-1 by TS92 on the activation of Rac1 and p47<sup>phox</sup> in ECs when monocytes adhere to ECs. Figure 2B demonstrated that inhibition of LOX-1 markedly attenuated the membrane translocation of Rac1 and p47<sup>phox</sup> in ECs caused by monocyte adhesion. The enhanced NADPH oxidase activity induced in ECs by monocyte adhesion was markedly reduced by pretreatment of ECs with TS92 (Fig. 2C). The phosphorylation of NF- $\kappa$ B in ECs induced by monocyte adhesion was also suppressed by preincubation of ECs with 5  $\mu\text{g}/\text{ml}$  TS92 for 1 h before adding monocytes (Fig. 2D).


Western blotting demonstrated that pretreatment of ECs with TS92 suppressed the increased expression of MCP-1, ICAM-1, TF, and PAI-1 in ECs caused by monocyte adhesion (Fig. 3A). To confirm this finding, we silenced LOX-1 by siRNA. Fluorescent immunohistochemistry demonstrated that the siRNA treatment for knockdown of LOX-1 decreased LOX-1 protein expression by approximately 75% compared with scrambled siRNA (Fig. 3B). Similar results regarding molecular expression were obtained with silencing of LOX-1 by siRNA to the treatment with TS92 (Fig. 3C).

These results indicated the integral role of LOX-1 in monocyte adhesion-triggered NADPH oxidase-dependent signaling pathways.

### Effect of inhibition of LOX-1 on Akt/eNOS phosphorylation

Figure 4A,B shows the time course of Akt and eNOS phosphorylation induced in ECs by monocyte adhesion, indicating that monocyte adhesion enhanced Akt and eNOS phosphorylation 15 min after adding monocytes to ECs and the levels of Akt and eNOS phosphorylation returned to control





**Fig. 1.** Effect of monocyte adhesion on redox signaling pathway in ECs. **A:** Time course of intracellular ROS generation in ECs in response to monocyte adhesion (0, 15, 30, and 60 min). Bars are the means  $\pm$  SD of quantitative fluorescent analyses from four separate experiments. Scale bars, 100  $\mu$ m. **B:** Effects of 10  $\mu$ mol/L DPI and 10 mmol/L NAC on ROS generation induced in ECs by monocyte adhesion. ROS generation levels were measured 60 min after adding monocytes. Bars are the means  $\pm$  SD of quantitative analyses from three separate experiments. Scale bars, 100  $\mu$ m. **C:** Effect of monocyte adhesion on membrane translocation of Rac1 and p47<sup>phox</sup> in ECs 30 min after adding monocytes. Data are expressed as the means  $\pm$  SD of quantitative densitometric analyses from four separate experiments. Immunoblots were from an experiment representative of four similar experiments. **D:** Phosphorylation of NF- $\kappa$ B p65 in ECs 1 h after adding monocytes. Monocytes ( $5 \times 10^5$  cells) were added to confluent ECs pretreated with or without 10  $\mu$ mol/L DPI and 10 mmol/L NAC for 30 min before adding monocytes. Representative immunoblots from three similar experiments are shown at the top. Data are the means  $\pm$  SD of densitometric analyses from three separate experiments. \* $P < 0.01$ , <sup>i</sup> $P < 0.0001$ , \*\* $P < 0.0005$ , and <sup>iii</sup> $P < 0.05$ .

with further incubation. However, NO production was not altered by monocyte adhesion 15 min after adding monocytes (data not shown). Monocyte adhesion-triggered Akt and eNOS phosphorylation in ECs was prevented by pretreatment of ECs with TS92, indicating that monocyte adhesion mediates Akt/eNOS phosphorylation via LOX-1 in ECs (Fig. 4C,D). The same concentration of antibody isotype control IgG as TS92 had a negligible effect on eNOS phosphorylation in the presence or absence of monocyte adhesion (Fig. 4D).

#### Effect of inhibition of LOX-1 on eNOS expression

Monocyte adhesion decreased eNOS expression 18 h after adding monocytes, which was prevented by pretreatment with TS92 (Fig. 5A), whereas DPI, a relatively specific inhibitor of NADPH oxidase, also attenuated monocyte adhesion-triggered downregulation of eNOS protein expression (Fig. 5B). This suggests significant interaction between decreased eNOS expression and LOX-1-mediated ROS generation in monocyte-EC interaction.

#### Role of LOX-1, ICAM-1, and VCAM-1 in Ca<sup>2+</sup> signaling


To further determine the mechanism(s) by which monocyte adhesion activates redox-signaling pathway in ECs through LOX-1, we focused on monocyte attachment-induced Ca<sup>2+</sup>

signaling. Monocyte attachment exerted a rapid and transient increase in [Ca<sup>2+</sup>]<sub>i</sub> in ECs as described previously (Ziegelstein et al., 1994; Sakamoto et al., 2005). Figure 6A shows the values of endothelial [Ca<sup>2+</sup>]<sub>i</sub> in response to monocyte attachment in the presence of external Ca<sup>2+</sup> when ECs were pretreated with 3, 5, and 10  $\mu$ g/ml TS92 for 1 h, indicating that inhibition of LOX-1 by TS92 suppressed monocyte attachment-induced [Ca<sup>2+</sup>]<sub>i</sub> increase in ECs ( $P < 0.0001$ ). There was no significant difference in the suppressive effect on monocyte attachment-induced [Ca<sup>2+</sup>]<sub>i</sub> increase among 3, 5, and 10  $\mu$ g/ml TS92 treatment. Control antibody of IgG (5  $\mu$ g/ml) did not change monocyte attachment-induced [Ca<sup>2+</sup>]<sub>i</sub> increase in ECs (Fig. 6A). In addition, inhibition of ICAM-1 and VCAM-1 suppressed monocyte attachment-induced [Ca<sup>2+</sup>]<sub>i</sub> increase in ECs similar to inhibition of LOX-1 ( $P < 0.0001$ , each, data not shown). Furthermore, inhibition of LOX-1 by TS92 at a concentration of 5  $\mu$ g/ml blocked both intracellular Ca<sup>2+</sup> mobilization and Ca<sup>2+</sup> influx in response to monocyte attachment in ECs ( $P < 0.0001$ , each, Fig. 6B).

#### Role of LOX-1 in monocyte adhesion to ECs

We then examined the effect of inhibition of LOX-1 on monocyte adhesion to ECs. Pretreatment of ECs with TS92 for 1 h before adding monocytes decreased monocyte adhesion to






**Fig. 2.** Effect of inhibition of LOX-1 on ROS generation (A), Rac1 and p47<sup>phox</sup> membrane translocation (B) NADPH oxidase activity (C), and NF-κB phosphorylation (D) in ECs by monocyte adhesion after 60 min. A: Near-confluent ECs in 60-mm dishes were pretreated with or without 5 μg/ml antibodies to LOX-1 (TS92), ICAM-1, VCAM-1, and PECAM-1 for 1 h and ROS generation was determined 60 min after adding monocytes. Bars are the means ± SD of quantitative analyses from four separate experiments. Scale bars, 100 μm. B: Monocytes ( $1 \times 10^6$  cells) were added to ECs in 100-mm dishes pretreated with or without TS92 for 1 h. After 30 min of coculture, Rac1 and p47<sup>phox</sup> membrane translocation was determined. Data are the means ± SD of densitometric analyses of Western blotting from four separate experiments. C: Endothelial NADPH oxidase activity was measured with or without inhibition of LOX-1 15 min after adding monocytes. Treatment of endothelial homogenates with DPI abolished the enzymatic activity of NADPH oxidase. Data are the means ± SD from five separate experiments. D: Monocytes ( $5 \times 10^5$  cells) were added to confluent ECs in 60-mm dishes pretreated with or without 5 μg/ml TS92 for 1 h. After 1 h of incubation with monocytes, NF-κB p65 phosphorylation in ECs was determined. Data are expressed as means ± SD of densitometric analyses of Western blotting from three separate experiments. Representative immunoblots from three similar experiments are shown. \* $P < 0.0001$ , † $P < 0.0005$ , and \*\* $P < 0.001$ .



ECs by  $47 \pm 6\%$ , compared with control (Fig. 7,  $P < 0.01$ ). Control with nonimmune IgG had a negligible effect on monocyte adhesion. We pretreated ECs with 10 ng/ml TNF- $\alpha$  and 100  $\mu$ g/ml oxidized LDL overnight, which enhanced monocyte adhesion to ECs (Fig. 7,  $P < 0.001$ , each). The

TNF- $\alpha$ - and oxidized LDL-induced monocyte adhesion was markedly reduced by inhibition of LOX-1 by TS92 (Fig. 7,  $P < 0.01$ , each). Control with nonimmune IgG did not significantly affect the monocyte adhesion with or without TNF- $\alpha$  or oxidized LDL activation.



**Fig. 3.** Effect of inhibition of LOX-1 by TS92 (A) or siRNA (C) on the increased expression of MCP-1, ICAM-1, TF, and PAI-1 induced in ECs by monocyte adhesion. **A:** ECs were pretreated with TS92 for 1 h before adding monocytes. After 18 h of coculture, Western blotting of MCP-1, ICAM-1, TF, and PAI-1 was performed and the same filters were re-probed with an anti-GAPDH antibody for normalization of cell lysates. Data are expressed as means  $\pm$  SD of ratios of each expression to GAPDH of densitometric analyses from five separate experiments. Representative immunoblots from five similar experiments are shown at the top. \* $P < 0.01$  and  $^{\dagger}P < 0.05$ . **B:** Effect of knockdown of LOX-1 by siRNA on LOX-1 protein expression in ECs. LOX-1 protein expression was determined by fluorescent immunohistochemistry and the data were quantitatively analyzed by the ImageJ. \* $P < 0.0001$ . **C:** Endothelial LOX-1 was inhibited by siRNA and monocytes were then added. Data are expressed as means  $\pm$  SD of three independent experiments. Representative immunoblots from three similar experiments are shown. \* $P < 0.01$  and  $^{\dagger}P < 0.05$ .







Fig. 3. (Continued)



**Fig. 4.** Role of LOX-1 in monocyte adhesion-triggered Akt/eNOS activation in ECs. Time course of Akt (A) and eNOS (B) phosphorylation induced in ECs by monocyte adhesion up to 60 min after adding monocytes. Nonphosphorylated expression of Akt and eNOS was not significantly altered by monocyte adhesion up to 60 min. Data are expressed as means  $\pm$  SD of ratios of each phosphorylated expression to nonphosphorylated expression of densitometric analyses from three separate experiments. Representative immunoblots from three similar experiments are shown. Effect of inhibition of LOX-1 by TS92 on increased phosphorylation of Akt (C) and eNOS (D) 15 min after adding monocytes. Data are expressed as means  $\pm$  SD of ratios of each phosphorylated expression to nonphosphorylated expression of three separate experiments. The same concentration of control with nonimmune IgG had a negligible effect on eNOS phosphorylation and expression in the presence and absence of monocyte adhesion. Representative immunoblots of three similar experiments are shown. \* $P < 0.01$  and  $^{\dagger}P < 0.05$ .




Fig. 5. Effect of inhibition of LOX-1 by TS92 (A) and DPI (B) on monocyte adhesion-triggered downregulation of eNOS protein expression 18 h after adding monocytes. Data of Western blotting are expressed as means  $\pm$  SD of four separate experiments. \* $P < 0.01$ .

### Interaction between $Ca^{2+}$ and NADPH oxidase/ROS

The finding (Hu et al., 2002) that the inhibition of ROS attenuates  $Ca^{2+}$  signaling in ECs prompted us to further examine the cross-talk between  $Ca^{2+}$  signaling and ROS generation in monocyte-EC interaction. Pretreatment of ECs with 10  $\mu$ Mol/L BAPTA-AM, a  $Ca^{2+}$  chelator, for 30 min indicated that  $Ca^{2+}$  chelation attenuated the membrane translocation of Rac1 and p47<sup>phox</sup> induced in ECs by monocyte adhesion 30 min after adding monocytes (Fig. 8A). Monocyte adhesion-induced ROS generation in ECs was markedly inhibited by pretreatment with BAPTA-AM similar to inhibition of NADPH oxidase by DPI (Fig. 8B). We finally examined the effect of inhibition of NADPH oxidase on monocyte attachment-triggered  $[Ca^{2+}]_i$  increase in ECs. Figure 8C shows that inhibition of NADPH oxidase by DPI induced a suppression of monocyte attachment-induced  $[Ca^{2+}]_i$  similar to  $Ca^{2+}$  chelation by BAPTA-AM in the presence of external  $Ca^{2+}$ .

### Discussion

The present study shows that monocyte adhesion-triggered NADPH oxidase-dependent, Akt/eNOS and  $Ca^{2+}$  signaling pathways are mediated via LOX-1 independent of the oxidized LDL-LOX-1 axis in ECs.

The binding of oxidized LDL to LOX-1 reportedly generates superoxide in ECs, which is canceled by the antibody to LOX-1 (Cominacini et al., 2000). It was also reported that the antibody

to LOX-1 suppresses NADPH oxidase-dependent ROS generation induced by remnant lipoprotein particles (RLPs), suggesting that some molecule(s) of RLPs may bind to LOX-1 (Shin et al., 2004). In fact, LOX-1 has been shown to recognize phosphatidylserine and negatively charged phospholipids (Kakutani et al., 2000). In the present study, we found that monocyte adhesion increased Rac1 and p47<sup>phox</sup> membrane translocation, NADPH oxidase activity, ROS generation, NF- $\kappa$ B phosphorylation, and redox-sensitive molecular expression in the absence of oxidized LDL in ECs, which was blocked by pretreatment of ECs with DPI and TS92. This is, to our knowledge, the first evidence to clearly show that NADPH oxidase-dependent redox signaling pathway through LOX-1 is independent of an oxidized LDL-LOX-1 axis in monocyte-EC interaction. It would be of interest to identify the molecule(s) in monocytes, which activate endothelial LOX-1, and this issue should be extensively investigated.

Li et al. (2001) suggested LOX-1-mediated Akt activation by oxidized LDL in cultured EC. However, little was known about the Akt/eNOS signaling in monocyte-EC interaction. We found that monocyte adhesion-triggered redox signaling pathway in ECs was accompanied by the transient activation of Akt/eNOS via LOX-1 15 min after adding monocytes, followed by normalization with further time intervals. However, NO production of culture medium did not significantly alter when the endothelial phosphorylation of Akt/eNOS was increased 15 min after adding monocytes because generated ROS probably increased NO breakdown (Martindale and Holbrook,





Fig. 6. Intracellular  $Ca^{2+}$  concentrations ( $[Ca^{2+}]_i$ ) in ECs in response to monocyte attachment. A: Effects of various concentrations of TS92 on the  $[Ca^{2+}]_i$  increase in ECs caused by monocyte attachment. ECs were pretreated with 3, 5, and 10  $\mu$ g/ml TS92 for 1 h and then monocytes were added. Antibody isotope control (5  $\mu$ g/ml) had a negligible effect on  $[Ca^{2+}]_i$  induced in ECs by monocyte attachment. B: Effect of inhibition of LOX-1 by TS92 on monocyte attachment-triggered intracellular  $Ca^{2+}$  mobilization and  $Ca^{2+}$  influx, which are defined in Materials and Methods Section. Data are expressed as means  $\pm$  SD of % fluorescent values of 100 ECs compared with control in an experiment representative of four similar experiments. \* $P < 0.0001$ .






**Fig. 7.** Effect of inhibition of LOX-1 by TS92 on monocyte adhesion to ECs pretreated with or without 10 ng/ml TNF- $\alpha$  or 100  $\mu$ g/ml oxidized LDL overnight. ECs were pretreated with TS92 or control antibody at concentrations of 5  $\mu$ g/ml for 1 h and washed three times before adding monocytes. After 30 min of coculture, adhered monocytes were measured as described in Materials and Methods Section. Data are expressed as means  $\pm$  SD of an experiment representative of three independent experiments ( $n = 6$ , each experiment). \* $P < 0.01$  versus each stimulation and \*\* $P < 0.001$  versus without stimulation.

2002), suggesting that monocyte adhesion-triggered Akt/eNOS activation via LOX-1 may be preventing action to ROS-mediated reducing NO bioavailability.

The gene expression of ICAM-1 and VCAM-1 has been shown to be regulated by ROS (Cominacini et al., 1997; Min et al., 2005). For our part, we observed that blockade of LOX-1, ICAM-1, and VCAM-1, but not PECAM-1, inhibited NADPH oxidase-dependent ROS generation induced in ECs by monocyte adhesion, as well as monocyte adhesion, suggesting that monocyte adhesion induces redox-sensitive and  $Ca^{2+}$  signaling pathways which are equally through LOX-1, ICAM-1, and VCAM-1. The results of our in vitro experiments suggest that any of LOX-1, ICAM-1, and VCAM-1, which are involved in monocyte adhesion, appears to induce identical signaling and that LOX-1 is not the sole mediator signaling upon monocyte adhesion.

Since LOX-1 is constitutively expressed in ECs, one would expect that circulating nonactivated monocytes would be able to bind to endothelium through LOX-1 in physiologic conditions. The present study showed that proinflammatory molecules and compounds such as TNF- $\alpha$  and oxidized LDL markedly enhanced monocyte adhesion to cultured ECs via LOX-1. It was reported that a major part of enhanced adhesiveness in ECs induced by CRP and glucose stimuli is attributable to LOX-1 (Li et al., 2003, 2004), suggesting that LOX-1 plays a role in monocyte adhesion in inflammation and diabetes mellitus. Taken together, the present study suggests



**Fig. 8.** Cross-talk between  $Ca^{2+}$  and NADPH oxidase/ROS in monocyte adhesion to ECs. Effect of  $Ca^{2+}$  chelation by 10  $\mu$ mol/L BAPTA-AM on Rac1 and p47<sup>phox</sup> activation (A) and ROS generation (B). ECs were pretreated with or without 10  $\mu$ mol/L BAPTA-AM for 30 min and the activation of Rac1 and p47<sup>phox</sup> was determined by membrane translocation 30 min after adding monocytes, whereas ROS generation levels were measured 60 min after adding monocytes. A: Rac1 and p47<sup>phox</sup> levels in membrane and cytosol fractions of ECs. Data are the means  $\pm$  SD of densitometric analyses of Western blotting from three separate experiments. B: Representative photomicrographs of ROS generation from three similar experiments are shown. Bars are the means  $\pm$  SD of quantitative analyses from three separate experiments. Scale bars, 100  $\mu$ m. C: Effect of inhibition of NADPH oxidase by 10  $\mu$ mol/L DPI on monocyte attachment-induced  $[Ca^{2+}]_i$  increase in ECs in the presence of external  $Ca^{2+}$ . Data are expressed as means  $\pm$  SD of % fluorescent values of 100 ECs compared with control in an experiment representative of three similar experiments. \* $P < 0.001$ , <sup>†</sup> $P < 0.005$ , and \*\* $P < 0.0001$ .



that in some proatherogenic situations, nonactivated or activated circulating monocytes can bind to activated ECs via LOX-1.

We have recently shown that BAPTA-AM prevents the activation of NF- $\kappa$ B and the enhancement of TF expression induced in ECs by monocyte adhesion, indicating Ca<sup>2+</sup> signaling is upstream of NF- $\kappa$ B in monocyte adhesion to ECs (Sakamoto et al., 2005). However, the potential cross-talk between ROS and Ca<sup>2+</sup> signaling is still poorly understood. NADPH oxidase reportedly affects Ca<sup>2+</sup> signaling in ECs (Hu et al., 2002). Zimmerman et al. (2005) also reported that NADPH oxidase-derived superoxide modulates angiotensin II-stimulated influx of extracellular Ca<sup>2+</sup> in neural cells. In contrast, Price et al. (2003) showed that Ca<sup>2+</sup> signaling regulates the membrane translocation and activation of Rac1 and p47<sup>phox</sup> in response to certain agonists. These findings suggest the cross-talk between that NADPH oxidase-dependent ROS and Ca<sup>2+</sup>. In the present study, we found Ca<sup>2+</sup>-dependent Rac1 and p47<sup>phox</sup> activation in ECs caused by monocyte adhesion, and also showed that inhibition of ROS generation suppressed monocyte attachment-triggered Ca<sup>2+</sup> signaling in the same culture system, indicating that Ca<sup>2+</sup> signaling is both upstream and downstream of NADPH oxidase and ROS. Our study demonstrates the potential cross-talk between Ca<sup>2+</sup> signaling and NADPH oxidase-dependent ROS in monocyte-EC interaction. This might open new avenues in understanding the pathogenesis of endothelial dysfunction.

Although we showed that monocytes adhesion activated Rac1 and p47<sup>phox</sup> and generated ROS via LOX-1 in ECs, the issue raised by the present study is that ROS generated in adhered monocytes other than ECs might be responsible for the observed molecular changes in ECs as Cathcart (2004) reported, even if monocytes were extensively washed out. Further study is needed to clarify the role of monocyte-derived ROS in monocyte adhesion-induced endothelial signaling and molecular changes.

Endothelial dysfunction plays a pivotal role in cardiovascular diseases including coronary artery disease, hypertension, stroke, and peripheral artery disease. In the presence or absence of LOX-1 activation by oxidized LDL, angiotensin II, etc., monocyte adhesion induces endothelial responses including ROS generation, reducing NO synthesis, increased permeability, and impaired coagulation, and fibrinolysis, resulting in the acceleration of endothelial dysfunction. Our results demonstrate that monocyte adhesion-triggered redox and Ca<sup>2+</sup> signaling were induced in ECs independent of oxidized-LDL, and these NADPH oxidase- and Ca<sup>2+</sup> signaling-dependent NF- $\kappa$ B signaling pathways were inhibited by blocking LOX-1. Our study also showed that, with or without oxidized-LDL, LOX-1 can participate in monocyte adhesion in certain situations, although LOX-1 activation is known to induce ICAM-1 and VCAM-1 on ECs. Therefore, our study has broad implications for its insight into the signaling pathways of endothelial dysfunction caused by monocyte adhesion and highlights LOX-1-mediated signaling pathways as an attractive target of cardiovascular disease.

## Literature Cited

- Cathcart MK. 2004. Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: Contribution to atherosclerosis. *Arterioscler Thromb Vasc Biol* 24:23–28.
- Cominacini L, Garbin U, Pasini AF, Davoli A, Campagnola M, Contessi GB, Pastorino AM, Lo Cascio V. 1997. Antioxidants inhibit the expression of intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 induced by oxidized LDL on human umbilical vein endothelial cells. *Free Radic Biol Med* 22:117–127.
- Cominacini L, Pasini AF, Garbin U, Davoli A, Tosetti ML, Campagnola M, Rigoni A, Pastorino AM, Lo Cascio V, Sawamura T. 2000. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF- $\kappa$ B through an increased production of intracellular reactive oxygen species. *J Biol Chem* 275:12633–12638.
- Ejiri J, Inoue N, Kobayashi S, Shiraki R, Otsui K, Honjo T, Takahashi M, Ohashi Y, Ichikawa S, Terashima M, Mori T, Awano K, Shinke T, Shite J, Hirata K, Yokozaki H, Kawashima S, Yokoyama M. 2005. Possible role of brain-derived neurotrophic factor in the pathogenesis of coronary artery disease. *Circulation* 112:2114–2120.
- Fischer D, Bhattacharya R, Osburg B, Bickel U. 2005. Inhibition of monocyte adhesion on brain-derived endothelial cells by NF-kappaB decoy/polyethylenimine complexes. *J Gene Med* 7:1063–1076.
- Hu Q, Yu ZX, Ferrans VJ, Takeda K, Irani K, Ziegelstein RC. 2002. Critical role of NADPH oxidase-derived reactive oxygen species in generating Ca<sup>2+</sup> oscillations in human aortic endothelial cells stimulated by histamine. *J Biol Chem* 277:32546–32551.
- Ishibashi T, Sakamoto T, Ohkawara H, Nagata K, Sugimoto K, Sakurada S, Sugimoto N, Watanabe A, Yokoyama K, Sakamoto N, Kurabayashi M, Takuwa Y, Maruyama Y. 2003. Integral role of RhoA activation in monocyte adhesion-triggered tissue factor expression in endothelial cells. *Arterioscler Thromb Vasc Biol* 23:681–687.
- Kakutani M, Masaki T, Sawamura T. 2000. A platelet-endothelium interaction mediated by lectin-like oxidized low-density lipoprotein receptor-1. *Proc Natl Acad Sci USA* 97:360–364.
- Li DY, Chen HJ, Mehta JL. 2001. Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized-LDL and reduction in PKB phosphorylation. *Cardiovasc Res* 52:130–135.
- Li L, Sawamura T, Renier G. 2003. Glucose enhances endothelial LOX-1 expression: Role for LOX-1 in glucose-induced human monocyte adhesion to endothelium. *Diabetes* 52:1843–1850.
- Li L, Roumeliotis N, Sawamura T, Renier G. 2004. C-reactive protein enhances LOX-1 expression in human aortic endothelial cells: Relevance of LOX-1 to C-reactive protein-induced endothelial dysfunction. *Circ Res* 95:877–883.
- Libby P. 2002. Inflammation in atherosclerosis. *Nature* 420:868–874.
- Martindale JL, Holbrook NJ. 2002. Cellular response to oxidative stress: Signaling for suicide and survival. *J Cell Physiol* 192:1–15.
- Min JK, Kim YM, Kim SW, Kwon YY, Hwang IK, Won MH, Rho J, Kwon YG. 2005. TNF-related activation-induced cytokine enhances leukocyte adhesiveness: Induction of ICAM-1 and VCAM-1 via TNF receptor-associated factor and protein kinase C-dependent NF-kappaB activation in endothelial cells. *J Immunol* 175:531–540.
- Nagata K, Ishibashi T, Sakamoto T, Nakazato K, Seino Y, Yokoyama K, Ohkawara H, Teramoto T, Maruyama Y. 2001. Effects of blockade of the renin-angiotensin system on tissue factor and plasminogen activator inhibitor-1 synthesis in human cultured monocytes. *J Hypertens* 19:775–783.
- Naïto Y, Yamada T, Uti-Tei K, Morishita S, Saigo K. 2004. siDirect: Highly effective, target-specific siRNA design software for mammalian RNA interference. *Nucleic Acids Res* 32:W124–W129 (Web Server issue).
- Ohkawara H, Ishibashi T, Sakamoto T, Sugimoto K, Nagata K, Yokoyama K, Sakamoto N, Kamioka M, Matsuoka I, Fukuhara S, Sugimoto N, Takuwa Y, Maruyama Y. 2005. Thrombin-induced rapid geranylgeranylation of RhoA as an essential process for RhoA activation in endothelial cells. *J Biol Chem* 280:10182–10188.
- Price LS, Langeslag M, ten Klooster JP, Hordijk PL, Jalink K, Collard JG. 2003. Calcium signaling regulates translocation and activation of Rac. *J Biol Chem* 278:39413–39421.
- Ross R. 1999. Atherosclerosis: An inflammatory disease. *N Engl J Med* 340:115–126.
- Sakamoto T, Ishibashi T, Sakamoto N, Sugimoto K, Egashira K, Ohkawara H, Nagata K, Yokoyama K, Kamioka M, Ichiki T, Sugimoto N, Kurabayashi M, Suzuki K, Takuwa Y, Maruyama Y. 2005. Endogenous NO blockade enhances tissue factor expression via increased Ca<sup>2+</sup> influx through MCP-1 in endothelial cells by monocyte adhesion. *Arterioscler Thromb Vasc Biol* 25:2005–2011.
- Sakamoto T, Ishibashi T, Sugimoto K, Sakamoto N, Ohkawara H, Niinuma M, Nagata K, Kamioka M, Sugimoto N, Watanabe A, Kurabayashi M, Takuwa Y, Maruyama Y. 2007. RhoA-dependent PAI-1 gene expression induced in endothelial cells by monocyte adhesion mediates geranylgeranyl transferase I and Ca<sup>2+</sup> signaling. *Atherosclerosis* 193:44–54.
- Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T, Masaki T. 1997. An endothelial receptor for oxidized low-density lipoprotein. *Nature* 386:73–77.
- Shibuki K, Okada D. 1991. Endogenous nitric oxide release required for long-term synaptic depression in the cerebellum. *Nature* 349:326–328.
- Shin HK, Kim YK, Kim KY, Lee JH, Hong KW. 2004. Remnant lipoprotein particles induce apoptosis in endothelial cells by NAD(P)H oxidase-mediated production of superoxide and cytokines via lectin-like oxidized low-density lipoprotein receptor-1 activation: Prevention by cilostazol. *Circulation* 109:1022–1028.
- Tsukahara H, Gordienko DV, Golligorsky MS. 1993. Continuous monitoring of nitric oxide release from human umbilical vein endothelial cells. *Biochem Biophys Res Commun* 193:722–729.
- Yokoyama K, Ishibashi T, Yi-qiang L, Nagayoshi A, Teramoto T, Maruyama Y. 1998. Interleukin-1beta and interleukin-6 increase levels of apolipoprotein B mRNA and decrease accumulation of its protein in culture medium of HepG2 cells. *J Lipid Res* 39:103–113.
- Yokoyama K, Ishibashi T, Ohkawara H, Kimura J, Matsuoka I, Sakamoto T, Nagata K, Sugimoto K, Sakurada S, Maruyama Y. 2002. HMG-CoA reductase inhibitors suppress intracellular calcium mobilization and membrane current induced by lysophosphatidylcholine in endothelial cells. *Circulation* 105:962–967.
- Ziegelstein RC, Corda S, Pili R, Passaniti A, Lefler D, Zweier JL, Fraticelli A, Capogrossi MC. 1994. Initial contact and subsequent adhesion of human neutrophils or monocytes to human aortic endothelial cells releases an endothelial intracellular calcium store. *Circulation* 90:1899–1907.
- Zimmerman MC, Sharma RV, Davison RL. 2005. Superoxide mediates angiotensin II-induced influx of extracellular calcium in neural cells. *Hypertension* 45:717–723.



## Evidence for Increased Methylglyoxal in the Vasculature of Women With Preeclampsia Role in Upregulation of LOX-1 and Arginase

Sowndramalingam Sankaralingam, Han Xu, Yanyan Jiang, Tatsuya Sawamura, Sandra T. Davidge

**Abstract**—Preeclampsia is characterized by vascular endothelial dysfunction partly attributed to oxidative stress. In the vasculature of preeclamptic women, we have shown increased lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1) and arginase expression, which can contribute to vascular oxidative stress. However, the mechanisms of such upregulation are unknown. Methylglyoxal (MG) that plays a role in the vascular complications of diabetes mellitus and the development of hypertension can be one potential factor that can affect LOX-1 and arginase through its ability to induce oxidative stress in vascular cells. MG also reacts with lysine residues in proteins to generate advanced glycation end product, N<sup>ε</sup>-carboxy ethyl lysine, which also serves as a marker of MG. We hypothesized that markers of MG formation will be increased in the vasculature of preeclamptic women and that exogenous MG will induce oxidative stress by the upregulation of LOX-1 via arginase. We observed increased N<sup>ε</sup>-carboxy ethyl lysine expression in the vasculature of women with preeclampsia in comparison with normotensive pregnant women. Moreover, glyoxalase I and II, enzymes that detoxify MG, and glutathione reductase, which generates reduced glutathione, a cofactor for glyoxalase, are also reduced in preeclampsia. In cultured endothelial cells, MG increased arginase expression by 6 hours and LOX-1 expression by 24 hours. Inhibition of arginase or NO synthase significantly reduced MG-induced LOX-1 expression, superoxide levels, and nitrotyrosine staining. In conclusion, MG-induced LOX-1 expression is mediated via arginase upregulation likely because of uncoupling of NO synthase, which may have implications in preeclampsia. (*Hypertension*. 2009;54:897-904.)

**Key Words:** preeclampsia ■ methylglyoxal ■ LOX-1 ■ arginase ■ peroxynitrite ■ endothelium

Preeclampsia is a disorder of pregnancy characterized by hypertension and proteinuria occurring after the 20th week of gestation.<sup>1</sup> A history of hypertension, diabetes mellitus, hyperlipidemia, obesity, renal disease, and extremes of age are some of the risk factors for the development of preeclampsia. Preeclampsia is also characterized by inflammation, oxidative stress, and endothelial dysfunction.<sup>2,3</sup> The maternal vascular endothelial dysfunction is thought to occur because of the actions of factors and molecules released by the placenta into the maternal circulation.<sup>4</sup> Because diabetes mellitus is one of the risk factors for the development of preeclampsia, factors involved in vascular complications of diabetes mellitus may also influence the development and maintenance of vascular abnormalities and possibly hypertension in preeclampsia. One factor involved in the vascular complications of diabetes mellitus is methylglyoxal (MG).<sup>5,6</sup> MG also plays a role in the development of hypertension in spontaneously hypertensive rats.<sup>7,8</sup> Moreover, MG treatment resulted in increased blood pressure in Wistar Kyoto rats.<sup>9</sup>

Other than increasing blood pressure, MG induces oxidative stress, resulting in the generation of reactive oxygen species and peroxynitrite in cultured vascular smooth muscle cells.<sup>10,11</sup>

MG is a highly reactive dicarbonyl compound formed by both enzymatic and nonenzymatic processes from glucose, proteins, and amino acids.<sup>12</sup> The enzymatic sources of MG includes not only glucose but also fatty acids and proteins by the action of the enzymes, MG synthase, acetol-mono-oxygenase,<sup>13</sup> and semicarbazide-sensitive amine oxidase (SSAO),<sup>14</sup> respectively. MG is a highly reactive molecule that reacts with various amino acid residues in proteins to form advanced glycation end products (AGEs). Although AGEs can be formed from glyoxal as well, MG is the most reactive<sup>15</sup> and most important precursor for AGEs.<sup>6,16</sup> MG is degraded by the glyoxalase system.<sup>17</sup> Glyoxalase I catalyzes the conversion of hemithioacetyl (an adduct of reduced glutathione [GSH] and MG) into S-D-lactoylglutathione, which is acted on by glyoxalase II to regenerate GSH. Glutathione peroxidase and glutathione reductase (GR) play roles in the formation and regeneration of GSH that serve to detoxify MG.

Received April 25, 2009; first decision May 16, 2009; revision accepted July 22, 2009.

From the Department of Physiology (S.S., S.T.D.) and Departments of Obstetrics and Gynecology, Women and Children's Health Research Institute, Cardiovascular Research Group, Mazankowski Alberta Heart Institute (H.X., Y.J., S.T.D.), University of Alberta, Edmonton, Alberta, Canada; Vascular Physiology (T.S.), National Cardiovascular Center Research Institute, Osaka, Japan.

Correspondence to Sandra T. Davidge, Departments of Obstetrics and Gynecology and Physiology, 232 HMRC, University of Alberta, Edmonton, Alberta, Canada T6G 2S2. E-mail sandra.davidge@ualberta.ca

© 2009 American Heart Association, Inc.

*Hypertension* is available at <http://hyper.ahajournals.org>

DOI: 10.1161/HYPERTENSIONAHA.109.135228



Whether MG is increased in the vasculature of women with preeclampsia and, if so, the mechanisms by which it affects endothelial function are unknown. We have shown previously in the vasculature of women with preeclampsia an enhanced expression of lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1).<sup>18</sup> LOX-1 is responsible for the binding, uptake, and degradation of oxidized low-density lipoprotein (oxLDL).<sup>19</sup> On activation via binding of oxLDL, LOX-1 generates superoxide via NADPH oxidase.<sup>20</sup> Other than LOX-1, increased arginase expression can also result in the generation of reactive oxygen species.<sup>21</sup> Increased arginase expression can deplete L-arginine<sup>22,23</sup> as a substrate, which can result in the decreased synthesis of NO<sup>24</sup> and the increased generation of superoxide by NO synthase (NOS).<sup>25,26</sup> This phenomenon by which NOS generates superoxide because of deficiency of the substrate, L-arginine, or the cofactor tetrahydrobiopterin is known as uncoupling of NOS.<sup>25,26</sup> Thus, overexpression of arginase in endothelial cells can lead to the uncoupling of NOS. Studies have shown increased arginase expression in both the placenta<sup>21</sup> and the maternal vasculature of women preeclampsia<sup>27</sup> and could contribute to decreased NO and enhanced superoxide formation. It is well known that MG can generate reactive oxygen species and peroxynitrite when added to vascular smooth muscle cells.<sup>10</sup> However, it is not known whether MG can generate reactive oxygen species via the arginase/LOX-1 pathway and contribute to endothelial dysfunction and oxidative stress in preeclampsia.

We hypothesize that markers of MG formation will be elevated in the maternal vasculature of women with preeclampsia. Also, MG will upregulate LOX-1 expression and oxidative stress markers via upregulation of arginase in endothelial cells in culture.

## Methods

### Subjects

Nonpregnant, pregnant, and preeclamptic subjects (6 per group) were recruited for this study at the Royal Alexandra Hospital (Edmonton, Alberta, Canada). Omental fat biopsies were obtained from these subjects during abdominal surgeries or cesarean section and stored at  $-80^{\circ}\text{C}$ . For details of the inclusion and exclusion criteria and the subject characteristics (Table S1), please see the online Data Supplement, available at <http://hyper.ahajournals.org>.

### Experimental Protocol

#### Immunohistochemistry

Our first aim was to assess the expression of AGEs, N<sup>ε</sup>-carboxy methyl lysine (CML) and N<sup>ε</sup>-carboxy ethyl lysine (CEL), that also serve as markers of MG in small arteries from nonpregnant, pregnant, and preeclamptic women. Although CML can be formed via a number of reactions, such as oxidative cleavage of Amadori products, Schiff base, auto-oxidation of glucose, and from MG, CEL is formed primarily from MG as its precursor.<sup>28</sup> CEL levels also serve as an index of MG in tissues.<sup>29</sup> We have, therefore, assessed both CML and CEL, which are considered markers of MG formation. The circulating concentrations of MG have been reported to vary from nanomoles per liter<sup>30</sup> to micromoles per liter,<sup>7,31</sup> the variations being attributed to analytic techniques.<sup>17</sup> However, the tissue levels of MG may be higher and also more important, because MG tends to react rapidly and readily with proteins in tissues.<sup>32</sup> We have, therefore, assessed markers of MG in tissues. The arteries in

omental fat biopsies were immunostained using rabbit monoclonal antibodies for CML (1:100) and CEL (1:100). Antirabbit secondary antibody (1:200 Alexa Fluor 488, Invitrogen Canada, Inc) was used to detect the primary antibody and was visualized using a fluorescein isothiocyanate filter.

We further assessed the expression of enzymes that are involved in the synthesis and degradation/detoxification of MG. We chose to measure the expression of SSAO, because it is widely studied in relation to MG formation.<sup>14</sup> We also assessed the expressions of glyoxalase I and II, enzymes that detoxify MG. In addition, we compared the expressions of glutathione peroxidase and GR, enzymes that generate GSH, a cofactor necessary for the detoxification of MG. Rabbit antibodies against human SSAO, glyoxalase I and II, as well as glutathione peroxidase and GR, were used at 1:100 dilution. Antirabbit secondary antibody (1:200 Alexa Fluor 488, Invitrogen Canada, Inc) was used to detect the primary antibody and was visualized using a fluorescein isothiocyanate filter.

#### Cell Culture Studies

The first aim of our cell culture study was to examine the effect of MG on LOX-1 and arginase expression in human umbilical vein endothelial cells. For details on human umbilical vein endothelial cell isolation please see the online Data Supplement.

Human umbilical vein endothelial cells were incubated with MG from 0 to 1000  $\mu\text{mol/L}$  for 24 hours on the basis of previous studies and our own preliminary studies.<sup>10,31</sup> On the basis of our preliminary experiments, a dose of 30  $\mu\text{mol/L}$  was chosen, and further studies were carried out at 6, 12, 18, and 24 hours. Interestingly, the plasma levels of MG in spontaneously hypertensive rats at 13 and 20 weeks are 30 and 33  $\mu\text{mol/L}$ , respectively, thus justifying the dose used.<sup>7</sup>

LOX-1 and arginase expressions were assessed by Western blot, as described previously.<sup>18,27</sup> Arginase activity was determined by measuring urea formation, also as described previously.<sup>33</sup> In some experiments, the arginase inhibitor (S)-(2-Boronoethyl)-L-cysteine (BEC) (100  $\mu\text{mol/L}$ ), NOS inhibitor N<sup>G</sup>-nitro-L-arginine methyl ester (L-NAME; 100  $\mu\text{mol/L}$ ), or peroxynitrite scavenger 5,10,15,20-tetrakis (4-sulfonatophenyl)prophyrinato iron (III), chloride (FeTPPS; 10  $\mu\text{mol/L}$ ) were used 30 minutes before the addition of MG to cells in culture.

In response to MG (30  $\mu\text{mol/L}$  for 24 hours), nitrotyrosine, a marker of peroxynitrite, was measured by immunocytochemistry using rabbit polyclonal antinitrotyrosine antibodies. Superoxide generation in live endothelial cells in response to MG (30  $\mu\text{mol/L}$ ) was measured at 24 hours using dihydroethidine.<sup>18</sup> To determine a role for arginase as a source of superoxide, cells were exposed to MG in the presence or absence of BEC, an arginase inhibitor, or L-NAME, an NOS inhibitor. Inhibition of superoxide generation by L-NAME, an NOS inhibitor, provides evidence for NOS as a source of superoxide and, therefore, suggests uncoupling of NOS.<sup>34</sup> In addition, 3,3'-diiododecylindocarbocyanine-labeled oxLDL uptake in response to MG in the presence or absence of BEC or L-NAME was performed as described previously.<sup>18</sup>

#### Statistical Analysis


Values are expressed as mean  $\pm$  SEM. Comparison of  $\geq 3$  groups was done using a 1-way ANOVA followed by a Tukey post hoc test. A  $P < 0.05$  was deemed significant.

## Results

### Arterial Expression of CEL, CML, and SSAO


We assessed the arterial expression of CEL and CML. Arteries from women with preeclampsia show significantly increased fluorescent staining for CEL and CML ( $26.7 \pm 3.5$  and  $22.6 \pm 3.1$  arbitrary units;  $P < 0.01$ ), respectively, primarily in the endothelial layer when compared with that of nonpregnant ( $3.9 \pm 1.4$  and  $5.7 \pm 1.1$  arbitrary units) and pregnant women ( $4.3 \pm 1.5$  and  $5.1 \pm 1.2$  arbitrary units; Figure 1).






**Figure 1.** Evidence for MG formation in preeclampsia. Representative images for CEL and CML staining (arrows) in the vasculature of nonpregnant (NON-PREG), pregnant (PREG), and preeclamptic (PE) women. Nuclei are shown in blue, whereas CEL and CML are shown in green. The images shown are magnified  $\times 100$ .

We also compared the expression of SSAO, an enzyme that generates MG. Interestingly, we observed an abundance of SSAO in arteries from women with preeclampsia when compared with arteries from nonpregnant and pregnant women (Figure 2).



**Figure 2.** SSAO expression in maternal vasculature. Representative images ( $\times 100$ ) show SSAO expression in the vasculature of nonpregnant (NON-PREG), pregnant (PREG), and preeclamptic (PE) women. Nuclei are shown in blue and staining for SSAO is shown in green. The summary graph shows mean SSAO expression from 6 subjects per group.  $*P < 0.05$ .



**Figure 3.** Glyoxalase I and II expression in maternal vasculature. Representative figures ( $\times 100$ ) for glyoxalase I (top) and II (bottom) expression in arteries from nonpregnant (NON-PREG), pregnant (PREG), and preeclamptic (PE) women. Nuclei are shown in blue and staining for glyoxalase I and II are shown in green. A summary graph from 6 subjects per group is shown.  $*P < 0.05$ .

### Arterial Expression of Glyoxalase I and II, GR, and Glutathione Peroxidase


We observed a significant decrease in the expression of glyoxalase I and II, the detoxifying enzymes in the vasculature of women with preeclampsia, when compared with arteries from normotensive pregnant women (Figure 3). Interestingly, GR that regenerates GSH, a cofactor necessary for the detoxification of MG, is reduced, whereas the expression of glutathione peroxidase, the enzyme that depletes GSH, is increased in the preeclamptic vasculature (Figure 4). These findings further strengthen the evidence for increased MG levels in the vasculature of women with preeclampsia.

### Endothelial Response to MG

#### Effect of MG on LOX-1 Expression

Endothelial cells treated with MG (0 to 1000  $\mu\text{mol/L}$ ) for 24 hours induced LOX-1 expression ( $\approx 100\%$ ,  $P < 0.05$ ) that was






**Figure 4.** Glutathione peroxidase and GR expression in maternal vasculature. Representative figures ( $\times 100$ ) for glutathione peroxidase (top) and GR (bottom) expression in arteries from nonpregnant (NON-PREG), pregnant (PREG), and preeclamptic (PE) women. Nuclei are shown in blue and staining for glutathione peroxidase and GR are shown in green. A summary graph from 6 subjects per group is shown.  $*P < 0.05$ .

maximal at a dose of  $30 \mu\text{mol/L}$  (Figure 5A). In the next set of experiments, MG ( $30 \mu\text{mol/L}$ ) induced  $\approx 100\%$  of the LOX-1 expression that was maximal at 24 hours (Figure 5B). Thus, MG increased LOX-1 expression in a dose- and time-dependent manner.

**Effect of MG on Arginase Expression and Activity**

Endothelial cells treated with MG (0 to  $1000 \mu\text{mol/L}$ ) for 6 hours showed significantly increased arginase II expression ( $\approx 70\%$ ;  $P < 0.05$ ) that was maximal at a dose of  $30 \mu\text{mol/L}$  (Figure 6A). Interestingly, endothelial cells treated with  $30 \mu\text{mol/L}$  of MG showed maximal expression as early as 6 hours (Figure 6B). Also, endothelial cells treated with MG (0 to  $30 \mu\text{mol/L}$ ) for 6 hours showed significantly increased arginase activity ( $0.053 \pm 0.020$  to  $0.133 \pm 0.020$  U/mg of protein;  $P < 0.05$ ) in a dose-dependent manner that was maximal at  $30 \mu\text{mol/L}$ .



**Figure 5.** Effect of MG on endothelial LOX-1 expression. Representative Western blot shows increased LOX-1 expression in endothelial cells (A) treated with MG (0 to  $1000 \mu\text{mol/L}$ ) for 24 hours and (B) treated with  $30 \mu\text{mol/L}$  of MG for 24 hours. LOX-1 expression was normalized to  $\alpha$ -tubulin. Graphs shown are a summary of 5 independent experiments.  $*P < 0.05$ .

**Effect of Arginase and NOS Inhibition on MG-Induced Oxidative Stress**


MG ( $30 \mu\text{mol/L}$ ) treatment for 24 hours resulted in an increased generation of superoxide compared with untreated cells ( $62.3 \pm 5.7$  versus  $25.7 \pm 3.5$ ;  $P < 0.01$ ) that was significantly reduced to similar levels after arginase ( $32.3 \pm 3.5$ ) or NOS inhibition ( $29.4 \pm 2.9$ ). In parallel to increased superoxide levels, nitrotyrosine staining was also increased by MG ( $30 \mu\text{mol/L}$ ) treatment for 24 hours ( $78.28 \pm 4.90$  versus  $17.34 \pm 2.00$ ;  $P < 0.01$ ) that was also reduced after arginase ( $38.13 \pm 3.70$ ) and NOS inhibition ( $3.20 \pm 0.60$ ).

**Effect of Arginase and NOS Inhibition on MG-Induced LOX-1 Expression and 3,3'-**

**Diocadecylindocarbocyanine-Labeled oxLDL Uptake**


We wanted to determine whether arginase upregulation and, therefore, the subsequent generation of oxidative stress by





**Figure 6.** Effect of MG on endothelial arginase II expression. Representative Western blot shows increased arginase II expression normalized to  $\alpha$ -tubulin in endothelial cells (A) treated with MG (0 to 1000  $\mu$ mol/L) for 6 hours and (B) treated with 30  $\mu$ mol/L of MG for 24 hours. Graphs shown are a summary of 5 independent experiments. \* $P < 0.05$ .

NOS played a role in the upregulation of LOX-1 in response to MG. MG (30  $\mu$ mol/L) treatment of endothelial cells for 24 hours upregulated LOX-1 expression by  $\approx 100\%$  ( $P < 0.05$ ), which was significantly reduced to control levels by arginase or NOS inhibition with BEC or L-NAME, respectively ( $P < 0.05$ ; Figure 7A). Because LOX-1 is involved in the binding and uptake of oxLDL, we also compared oxLDL uptake in response to MG using 3,3'-dioctadecylindocarbocyanine-labeled oxLDL (Figure S1 in the online Data Supplement). Treatment of endothelial cells with MG (30  $\mu$ mol/L) for 24 hours significantly increased oxLDL binding and uptake that were prevented by arginase and NOS inhibition.



**Figure 7.** Effect of arginase and NOS inhibition on LOX-1 expression. Representative Western blot showing increased LOX-1 expression in response to MG (30  $\mu$ mol/L) for 24 hours in the presence or absence of (A) BEC and L-NAME and (B) FeTPPS. Graph shows the summary of 5 independent experiments. \* $P < 0.05$  control (CON) vs MG; # $P < 0.05$  MG vs MG+BEC, MG+L-NAME, or MG+FeTPPS.

### Role of Peroxynitrite in MG-Induced LOX-1 Expression

Because arginase upregulation can ultimately lead to peroxynitrite formation by NOS in response to MG, we wanted to determine whether peroxynitrite was involved in the upregulation of LOX-1 in response to MG. MG (30  $\mu$ mol/L) treatment for 24 hours increased LOX-1 expression in endothelial cells that was significantly reduced to control levels by FeTPPS (peroxynitrite scavenger), confirming a role for peroxynitrite in MG-induced LOX-1 expression (Figure 7B).

### Discussion

In this study, we demonstrate for the first time evidence for MG formation in the vasculature of women with preeclampsia. This is supported by increased levels of CML and CEL, which are markers of MG formation in the vasculature.



Furthermore, SSAO, the enzyme that generates MG, is increased in preeclampsia, whereas the expressions of the glyoxalase enzymes that degrade MG are reduced. Moreover, the expression of GR that generates GSH is also reduced. In fact, this is the first report of AGE formation in the vasculature of women with preeclampsia. We further show that MG by upregulates LOX-1 expression via arginase.

Overexpression of glyoxalase I has been shown to inhibit AGE formation in bovine endothelial cells.<sup>16</sup> Our study demonstrates that decreased glyoxalase I and II expression in the vasculature of women with preeclampsia could have led to increased MG in the vasculature and, therefore, increased formation of CML and CEL. We also show an increased expression of SSAO in the vasculature of women with preeclampsia. Normally SSAO is involved in the deamination of aminoacetone<sup>35</sup> but in the process generates MG. Thus, we have evidence for greater production and reduced degradation of MG in the vasculature of women with preeclampsia.

MG plays a role in the development of hypertension<sup>36</sup> and oxidative stress.<sup>37</sup> It is suggested that MG may induce hypertension via different mechanisms, such as increasing vascular contractility, generating reactive oxygen species, and proliferating vascular smooth muscle in resistance arteries leading to vascular remodeling, ultimately resulting in enhanced vasoconstriction and, therefore, hypertension.<sup>17</sup> However, the role of MG in inducing hypertension and oxidative stress in preeclampsia is unknown. We have previously shown increased LOX-1<sup>18</sup> and arginase<sup>27</sup> expressions in the maternal vasculature of women with preeclampsia, when compared with normotensive pregnant women. We, therefore, explored the possibility that MG can affect these pathways.

Here we show that MG could be one factor involved in the upregulation of arginase and LOX-1 in preeclamptic vasculature. In response to MG, arginase inhibition significantly reduced MG-induced LOX-1 expression, suggesting a role for arginase in the upregulation of LOX-1. Importantly, in response to MG, arginase upregulation is maximal as early as 6 hours, whereas LOX-1 upregulation is maximal at 24 hours. This suggests that products generated because of arginase upregulation early in the response to MG may play a role in the upregulation of LOX-1. It is well known that NOS can generate superoxide. Our data show that increased superoxide production in response to MG is inhibitable by BEC or L-NAME to a similar extent, suggesting a role for arginase and, therefore, for NOS in possibly mediating the generation of reactive oxygen species. Inhibition of superoxide production by L-NAME suggests a role for uncoupling of NOS<sup>34</sup> as a source of superoxide in response to MG. In our study, we have used L-NAME as an inhibitor of all isoforms of NOS and, therefore, cannot identify the isoform of NOS that generates superoxide. Uncoupling of NOS can occur because of a deficiency of either L-arginine, the substrate, or tetrahydrobiopterin, the cofactor, depending on the isoform of NOS. Although all isoforms of NOS undergo uncoupling because of deficiency of tetrahydrobiopterin, it is primarily inducible NOS and neuronal NOS that undergo uncoupling because of L-arginine deficiency.<sup>38–41</sup> In our study, we show that MG can also induce peroxynitrite formation in endothelial cells. It

is possible that peroxynitrite can oxidize tetrahydrobiopterin and, thus, create deficiency leading to uncoupling of NOS.<sup>42</sup> Thus, in addition to the direct effect of arginase upregulation on depleting L-arginine, peroxynitrite generated because of arginase upregulation can also cause uncoupling of NOS. However, further studies are needed to characterize the mechanisms of uncoupling of NOS attributed to upregulation of arginase in endothelial cells in response to MG. Because arginase inhibition with BEC reduced superoxide generation by endothelial cells in response to MG, it is reasonable to speculate that arginase could be a source of superoxide. Interestingly, MG has also been shown to inactivate human Cu, Zn superoxide dismutase that can also result in increased superoxide levels.<sup>43</sup>

Our data show that MG can upregulate LOX-1 in endothelial cells; therefore, MG might directly or indirectly play a role in the development of atherosclerosis in cardiovascular diseases and also in inducing such abnormalities in the vasculature of women with preeclampsia. This could also partly explain the accumulation of oxLDL in the vasculature of women with preeclampsia,<sup>18</sup> a feature that is analogous to atherosclerosis. Other than oxLDL, AGEs can also bind to LOX-1 and can provide a feedforward progression to induce oxidative stress via the upregulation of LOX-1.<sup>44</sup>

The role of MG has been extensively studied in diabetes mellitus and its complications, such as diabetic nephropathy.<sup>5,45</sup> This is important because renal lesion, called glomerular endotheliosis, is known to occur in preeclampsia. Because MG is involved in renal complications of diabetes mellitus, it is tempting to speculate that MG could be involved in the renal complications of preeclampsia as well. In addition, AGEs have primarily been associated with complications of diabetes mellitus, and we have now evidence to suggest that vascular complications of preeclampsia may also be attributable to AGEs. In fact, we have previously shown increased expression of receptor for AGEs in the vasculature of women with preeclampsia.<sup>46</sup> All of these further support a role for MG and possibly AGEs in the vascular complications and oxidative stress that are features of preeclampsia.

### Perspectives

The role of MG in causing vascular complications of diabetes mellitus is well established.<sup>5,45</sup> The role of MG in the development of hypertension is emerging.<sup>5,7,8,45,47–49</sup> Diabetes mellitus, atherosclerosis, and hypertension are known risk factors for the development of preeclampsia. Therefore, factors that are involved in the above conditions may also play a role in the initiation and propagation of the disease process in preeclampsia. Our study provides evidence for increased levels of MG in the vasculature of women with preeclampsia. Moreover, novel mechanisms for MG-induced oxidative stress through arginase and LOX-1 in endothelial cells have been described. Recent studies suggest that preeclamptic women are prone to cardiovascular disease later in life.<sup>50</sup> Increased MG levels in the vasculature of these women might partly explain their susceptibility to develop cardiovascular complications. Our study has potential therapeutic



implications not only to prevent vascular complications of preeclampsia but also other hypertensive vascular disorders.

### Acknowledgments

We thank Donna Dawson from the Royal Alexandra Hospital for sample collection.

### Sources of Funding

This work was supported by grants from the Canadian Institutes for Health Research (CIHR). S.S. was supported by the Maternal-Fetal-Newborn Health and the Strategic Training Initiative in Research in Reproductive Health Sciences Training Programs of the CIHR, a full-time studentship from the Alberta Heritage Foundation for Medical Research (AHFMR), and a Junior Personnel Award from the Heart and Stroke Foundation of Canada. H.X. was supported by a summer studentship from the AHFMR. T.S. was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan; the Ministry of Health, Labour and Welfare of Japan; the National Institute of Biomedical Innovation; Japan Science and Technology Agency; and the New Energy and Industrial Technology Development Organization. S.T.D. is an AHFMR Scientist and a Canada Research Chair in Women's Cardiovascular Health.

### Disclosures

None.

### References

- Magee LA, Helewa M, Moutquin JM, von Dadelzen P, Cardew S, Cote AM, Douglas MJ, Firoz T, Gibson PS, Gruslin A, Lange I, Leduc L, Logan AG, Rey E, Senikas V, Smith GN, Bainbridge S, Chen XK, Xu H, Hutcheon J, Menzies J, Sankaralingam S, Xie F. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. *J Obstet Gynaecol Can.* 2008;30:S1.
- Roberts JM. Preeclampsia: what we know and what we do not know. *Semin Perinatol.* 2000;24:24–28.
- Roberts JM. Endothelial dysfunction in preeclampsia. *Semin Reprod Endocrinol.* 1998;16:5–15.
- Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of preeclampsia: linking placental ischemia/hypoxia with microvascular dysfunction. *Microcirculation.* 2002;9:147–160.
- Beisswenger PJ, Drummond KS, Nelson RG, Howell SK, Szwegold BS, Mauer M. Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. *Diabetes.* 2005;54:3274–3281.
- Bourajjaj M, Stehouwer CD, van Hinsbergh VW, Schalkwijk CG. Role of methylglyoxal adducts in the development of vascular complications in diabetes mellitus. *Biochem Soc Trans.* 2003;31:1400–1402.
- Wang X, Desai K, Chang T, Wu L. Vascular methylglyoxal metabolism and the development of hypertension. *J Hypertens.* 2005;23:1565–1573.
- Wang X, Desai K, Clausen JT, Wu L. Increased methylglyoxal and advanced glycation end products in kidney from spontaneously hypertensive rats. *Kidney Int.* 2004;66:2315–2321.
- Vasdev S, Ford CA, Lonerich L, Parai S, Gadag V, Wadhawan S. Aldehyde induced hypertension in rats: prevention by N-acetyl cysteine. *Artery.* 1998;23:10–36.
- Chang T, Wang R, Wu L. Methylglyoxal-induced nitric oxide and peroxynitrite production in vascular smooth muscle cells. *Free Radic Biol Med.* 2005;38:286–293.
- Wu L. The pro-oxidant role of methylglyoxal in mesenteric artery smooth muscle cells. *Can J Physiol Pharmacol.* 2005;83:63–68.
- Ray S, Ray M. Isolation of methylglyoxal synthase from goat liver. *J Biol Chem.* 1981;256:6230–6233.
- Casazza JP, Felver ME, Veech RL. The metabolism of acetone in rat. *J Biol Chem.* 1984;259:231–236.
- Yu PH, Wright S, Fan EH, Lun ZR, Gubisne-Harberle D. Physiological and pathological implications of semicarbazide-sensitive amine oxidase. *Biochim Biophys Acta.* 2003;1647:193–199.
- Kilhovd BK, Giardino I, Torjesen PA, Birkeland KI, Berg TJ, Thornalley PJ, Brownlee M, Hanssen KF. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. *Metabolism.* 2003;52:163–167.
- Shinohara M, Thornalley PJ, Giardino I, Beisswenger P, Thorpe SR, Onorato J, Brownlee M. Overexpression of glyoxalase-I in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. *J Clin Invest.* 1998;101:1142–1147.
- Chang T, Wu L. Methylglyoxal, oxidative stress, and hypertension. *Can J Physiol Pharmacol.* 2006;84:1229–1238.
- Sankaralingam S, Xu Y, Sawamura T, Davidge ST. Increased lectin-like oxidized low-density lipoprotein receptor-1 expression in the maternal vasculature of women with preeclampsia: role for peroxynitrite. *Hypertension.* 2009;53:270–277.
- Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T, Masaki T. An endothelial receptor for oxidized low-density lipoprotein. *Nature.* 1997;386:73–77.
- Cominacini L, Rigoni A, Pasini AF, Garbin U, Davoli A, Campagnola M, Pastorino AM, Lo Cascio V, Sawamura T. The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. *J Biol Chem.* 2001;276:13750–13755.
- Noris M, Todeschini M, Cassis P, Pasta F, Cappellini A, Bonazzola S, Macconi D, Maucci R, Porra F, Benigni A, Picciolo C, Remuzzi G. L-arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species. *Hypertension.* 2004;43:614–622.
- Li H, Meininger CJ, Hawker JR Jr, Haynes TE, Kepka-Lenhart D, Mistry SK, Morris SM Jr, Wu G. Regulatory role of arginase I and II in nitric oxide, polyamine, and proline syntheses in endothelial cells. *Am J Physiol Endocrinol Metab.* 2001;280:E75–E82.
- Waddington S, Cook HT, Reaveley D, Jansen A, Cattell V. L-arginine depletion inhibits glomerular nitric oxide synthesis and exacerbates rat nephrotic nephritis. *Kidney Int.* 1996;49:1090–1096.
- Xu W, Kaneko FT, Zheng S, Comhair SA, Janocha AJ, Goggans T, Thunnissen FB, Farver C, Hazen SL, Jennings C, Dweik RA, Arroliga AC, Erzurum SC. Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. *FASEB J.* 2004;18:1746–1748.
- Xia Y, Dawson VL, Dawson TM, Snyder SH, Zweier JL. Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. *Proc Natl Acad Sci U S A.* 1996;93:6770–6774.
- Vasquez-Vivar J, Kalyanaram B, Martasek P, Hogg N, Masters BS, Karoui H, Tordo P, Pritchard KA Jr. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. *Proc Natl Acad Sci U S A.* 1998;95:9220–9225.
- Sankaralingam S, Davidge ST. Role of arginase in the pathophysiology of preeclampsia [abstract]. *FASEB J.* 2008;22:758.755.
- Koito W, Araki T, Horiuchi S, Nagai R. Conventional antibody against N-epsilon-(carboxymethyl)lysine (CML) shows cross-reaction to N-epsilon-(carboxyethyl)lysine (CEL): immunochemical quantification of CML with a specific antibody. *J Biochem.* 2004;136:831–837.
- Ahmed MU, Brinkmann Frye E, Degenhardt TP, Thorpe SR, Baynes JW. N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. *Biochem J.* 1997;324(pt 2):565–570.
- McLellan AC, Phillips SA, Thornalley PJ. The assay of methylglyoxal in biological systems by derivatization with 1,2-diamino-4,5-dimethoxybenzene. *Anal Biochem.* 1992;206:17–23.
- Wang H, Meng QH, Gordon JR, Khandwala H, Wu L. Proinflammatory and proapoptotic effects of methylglyoxal on neutrophils from patients with type 2 diabetes mellitus. *Clin Biochem.* 2007;40:1232–1239.
- Shamsi FA, Partal A, Sady C, Glomb MA, Nagaraj RH. Immunological evidence for methylglyoxal-derived modifications in vivo: determination of antigenic epitopes. *J Biol Chem.* 1998;273:6928–6936.
- Corraliza IM, Campo ML, Soler G, Modolell M. Determination of arginase activity in macrophages: a micromethod. *J Immunol Methods.* 1994;174:231–235.
- Taylor NE, Maier KG, Roman RJ, Cowley AW Jr. NO synthase uncoupling in the kidney of Dahl S rats: role of dihydrobiopterin. *Hypertension.* 2006;48:1066–1071.
- Deng Y, Yu PH. Assessment of the deamination of aminoacetone, an endogenous substrate for semicarbazide-sensitive amine oxidase. *Anal Biochem.* 1999;270:97–102.



36. Vasdev S, Gill V, Singal P. Role of advanced glycation end products in hypertension and atherosclerosis: therapeutic implications. *Cell Biochem Biophys*. 2007;49:48–63.
37. Desai KM, Wu L. Free radical generation by methylglyoxal in tissues. *Drug Metabol Drug Interact*. 2008;23:151–173.
38. Bevers LM, Braam B, Post JA, van Zonneveld AJ, Rabelink TJ, Koomans HA, Verhaar MC, Joles JA. Tetrahydrobiopterin, but not L-arginine, decreases NO synthase uncoupling in cells expressing high levels of endothelial NO synthase. *Hypertension*. 2006;47:87–94.
39. Cardounel AJ, Xia Y, Zweier JL. Endogenous methylarginines modulate superoxide as well as nitric oxide generation from neuronal nitric-oxide synthase: differences in the effects of monomethyl- and dimethyl-arginines in the presence and absence of tetrahydrobiopterin. *J Biol Chem*. 2005;280:7540–7549.
40. Xia Y, Roman LJ, Masters BS, Zweier JL. Inducible nitric-oxide synthase generates superoxide from the reductase domain. *J Biol Chem*. 1998;273:22635–22639.
41. Xia Y, Tsai AL, Berka V, Zweier JL. Superoxide generation from endothelial nitric-oxide synthase. A Ca<sup>2+</sup>/calmodulin-dependent and tetrahydrobiopterin regulatory process. *J Biol Chem*. 1998;273:25804–25808.
42. Milstien S, Katusic Z. Oxidation of tetrahydrobiopterin by peroxynitrite: implications for vascular endothelial function. *Biochem Biophys Res Commun*. 1999;263:681–684.
43. Kang JH. Modification and inactivation of human Cu, Zn-superoxide dismutase by methylglyoxal. *Mol Cells*. 2003;15:194–199.
44. Inoue N, Sawamura T. Lectin-like oxidized LDL receptor-1 as extracellular chaperone receptor: its versatile functions and human diseases. *Methods*. 2007;43:218–222.
45. Mostafa AA, Randell EW, Vasdev SC, Gill VD, Han Y, Gadag V, Raouf AA, El Said H. Plasma protein advanced glycation end products, carboxymethyl cysteine, and carboxyethyl cysteine, are elevated and related to nephropathy in patients with diabetes. *Mol Cell Biochem*. 2007;302:35–42.
46. Cooke CL, Brockelsby JC, Baker PN, Davidge ST. The receptor for advanced glycation end products (RAGE) is elevated in women with preeclampsia. *Hypertens Pregnancy*. 2003;22:173–184.
47. Wang X, Chang T, Jiang B, Desai K, Wu L. Attenuation of hypertension development by aminoguanidine in spontaneously hypertensive rats: role of methylglyoxal. *Am J Hypertens*. 2007;20:629–636.
48. Wu L. Is methylglyoxal a causative factor for hypertension development? *Can J Physiol Pharmacol*. 2006;84:129–139.
49. Wu L, Juurlink BH. Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. *Hypertension*. 2002;39:809–814.
50. Craici I, Wagner S, Garovic VD. Preeclampsia and future cardiovascular risk: formal risk factor or failed stress test? *Ther Adv Cardiovasc Dis*. 2008;2:249–259.



# LOX-1 augments oxLDL uptake by lysoPC-stimulated murine macrophages but is not required for oxLDL clearance from plasma

David F. Schaeffer,<sup>1,\*</sup> Maziar Riazzy,<sup>1,\*</sup> Kuljit S. Parhar,<sup>\*</sup> Johnny H. Chen,<sup>\*</sup> Vincent Duronio,<sup>\*</sup> Tatsuya Sawamura,<sup>†</sup> and Urs P. Steinbrecher<sup>2,\*</sup>

Department of Medicine,<sup>\*</sup> University of British Columbia, Vancouver, Canada; Department of Vascular Physiology,<sup>†</sup> National Cardiovascular Research Institute, Osaka, Japan

**Abstract** Oxidized LDL (oxLDL) promotes lipid accumulation as well as growth and survival signaling in macrophages. OxLDL uptake is mainly due to scavenger receptors SR-AI/II and CD36. However, other scavenger receptors such as lectin-like oxLDL receptor-1 (LOX-1) may also play a role. We used mice with targeted inactivation of the LOX-1 gene to define the role of this receptor in the uptake of oxLDL and in activation of survival pathways. There was no difference in uptake or degradation of <sup>125</sup>I-oxLDL in unstimulated macrophages from wild-type and LOX-1 knockout mice and no difference in the rate of clearance of oxLDL from plasma in vivo. However, when expression of LOX-1 was induced with lysophosphatidylcholine, oxLDL uptake and degradation increased 2-fold in wild-type macrophages but did not change in LOX-1 knockout macrophages. Macrophages lacking LOX-1 showed the same stimulation of PKB phosphorylation and enhancement of survival by oxLDL as wild-type cells. These data show that LOX-1 does not alter the uptake of oxLDL in unstimulated macrophages and is not essential for the pro-survival effect of oxLDL in these cells. However, LOX-1 expression is highly inducible by lysophosphatidylcholine and pro-inflammatory cytokines, and if that occurred in macrophages within atheromas, LOX-1 could substantially increase oxLDL uptake by lesion macrophages.—Schaeffer, D. F., M. Riazzy, K. S. Parhar, J. H. Chen, V. Duronio, T. Sawamura, and U. P. Steinbrecher. LOX-1 augments oxLDL uptake by lysoPC-stimulated murine macrophages but is not required for oxLDL clearance from plasma. *J. Lipid Res.* 2009. 50: 1676–1684.

**Supplementary key words** apoptosis • lysophosphatidylcholine • macrophage • oxidized low density lipoprotein • scavenger receptor

This study was supported by grants from the Canadian Institutes of Health Research (U.P.S.) and the Heart and Stroke Foundation of British Columbia and Yukon (U.P.S. and V.D.); a fellowship from the Canadian Institutes of Health Research/Michael Smith Foundation for Health Research (D.F.S.); and a studentship from the Canadian Liver Foundation (K.S.P.).

Manuscript received 8 April 2009.

Published, JLR Papers in Press, April 9, 2009

DOI 10.1194/jlr.M900167-JLR200

The lectin-like oxidized LDL receptor (LOX-1) is a 50 kDa type II membrane receptor belonging to the C-type lectin family. It is expressed in vascular smooth muscle cells, macrophages, fibroblasts, and platelets (1, 2). It is reported to be upregulated in pathological conditions including hypertension, diabetes, and atherosclerosis. The potential role of LOX-1 in atherosclerotic process has been based on a number of observations. LOX-1 has the capability to bind, internalize, and degrade oxLDL (3). The activation of LOX-1 by oxLDL induces endothelial dysfunction and apoptosis (4–6). Furthermore LOX-1 is present in atheroma-derived cells and has been identified in animal and human atherosclerotic lesions in vivo (7, 8). Mehta et al. recently reported that in LDL receptor knockout mice, LOX-1 gene inactivation reduces the extent of atherosclerosis (9). The LOX-1 receptor has also been shown to mediate intracellular cell signaling events. For example, the binding of oxLDL to LOX-1 is reported to activate signaling via ERK that modulates the Bax/Bcl2 ratio in vascular smooth muscle cells and to activate NF- $\kappa$ B in endothelial cells (10).

LOX-1 is a member of the scavenger receptor family of multiligand receptors that are thought to play a role in innate immunity (11). Other members of this family expressed in macrophages include SRAI/II, CD36, macrophage receptor with collagenous structure (MARCO), scavenger receptor expressed in endothelial cells (SREC), and a transmembrane chemokine and receptor for phosphatidylserine and oxLDL, SR-PSOX/CXCL16 (11). Previous studies indicate that 30–40% of the degradation of extensively oxidized LDL by

**Abbreviations:** acLDL, acetylated low density lipoprotein; BMDM, bone marrow derived macrophages; lysoPC, lysophosphatidylcholine; M-CSF, macrophage colony-stimulating factor; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; oxLDL, oxidized low density lipoprotein.

<sup>1</sup>D. F. Schaeffer and M. Riazzy contributed equally to this work.

<sup>2</sup>To whom correspondence should be addressed.

e-mail: usteinbr@interchange.ubc.ca

Copyright © 2009 by the American Society for Biochemistry and Molecular Biology, Inc.